In addition to activation of plasma-related pathways, we also observed in naïve B cells that FCER2 was downregulated while SLAMF7 was upregulated suggesting significant activation of these cells in COVID-19 (Fig. 5f). The gene discussed is FCER2; the disease is COVID-19.